ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Home
/
insight
/
details

A Comparative Examination of Whole Genome and Whole Exome Sequencing

NextEdge Admin

02 Jan 2024

4 min 0 sec

Whole genome sequencing (WGS) and whole exome sequencing (WES) are two techniques used in genomic research and clinical genetics to analyze an individual’s DNA. Here are the key differences between the two:

1. Scope of Sequencing:

– Whole Genome Sequencing (WGS): It involves sequencing the entire genome of an organism, including both coding and non-coding regions. This provides a comprehensive view of an individual’s genetic makeup, covering all genes, intergenic regions, and regulatory elements.

– Whole Exome Sequencing (WES): It focuses specifically on the protein-coding regions of the genome, known as exons. Exons represent only about 1-2% of the entire genome but contain the majority of known disease-causing mutations.

2. Content Covered:

– WGS: It provides information about all genetic variations, including single nucleotide polymorphisms (SNPs), insertions, deletions, and structural variants throughout the genome.

– WES: It primarily targets exons, where most disease-associated variants are found. It may miss variations in non-coding regions and introns.

3. Data Volume:

– WGS: Produces a larger amount of data compared to WES since it covers the entire genome. This can make data storage, processing, and analysis more challenging.

– WES: Generates less data since it focuses on a smaller portion of the genome, making it more manageable in terms of storage and analysis.

4. Cost:

– WGS: Historically, whole genome sequencing has been more expensive than whole exome sequencing.

– WES: It has been a more cost-effective option for identifying coding region variants associated with diseases, making it a popular choice in clinical diagnostics.

5. Clinical Relevance:

– WGS: Provides a more comprehensive analysis and may be useful for identifying variants in non-coding regions and understanding complex genetic interactions. It can be valuable for diagnosing a broad range of genetic conditions.

– WES: Often used when the focus is on identifying variations within protein-coding regions, which are more directly linked to many known genetic disorders.

6. Application:

– WGS: Widely used in research settings for projects aiming to understand the entire genomic landscape, uncover new variants, and study population genetics.

– WES: Frequently used in clinical diagnostics, especially when focusing on known protein-coding genes associated with specific diseases.

The choice between WGS and WES depends on the specific goals of the study or clinical application, budget constraints, and the desired level of genomic coverage. Advances in sequencing technologies and decreasing costs may influence the preference for one method over the other in different contexts.

Related Tags

Whole genome sequencing (WGS)

genetics

whole exome sequencing (WES)

DNA

Unlocking Therapeutic Avenues: Targeted Drugs Tailored to Genetic Drivers in LungCancer

Precision Oncology and the Integration of Pharmacogenomic Insights

Top Reviews

No reviews yet